Research Article
Cost-Effectiveness of Oral Antidiabetic Drugs: A Prospective Multicenter Study of Real-World Patients
Table 9
Inverse-probability-weighted outcomes.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Note: inpatient cost, outpatient cost, medication cost, and total cost are measured with the unit of 1000 RMB. Inverse probability weighting needs enough observations in each treatment arm during estimation, and we therefore merge glibenclamide into the category “others.” The predictive margins are calculated after multivariate regressions. When calculating the predictive margins, covariates including age, sex, education, household income, type of medical insurance, city of residence, diabetes-related morbidities including AMI, hypertension, dyslipidemia, and stroke, duration of diabetes, alcoholic use, smoking, physical exercise, diet control, BMI, blood glucose level, HbA1c, blood pressure, TCH, TG, and EQ-5D score are controlled. |